{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:58:52Z","timestamp":1793746732898,"version":"4.6.1"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FDN-148413"],"award-info":[{"award-number":["FDN-148413"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.biopha.2021.111861","type":"journal-article","created":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T18:00:56Z","timestamp":1625335256000},"page":"111861","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Pharmacodynamic and pharmacokinetic profiles of a neurotensin receptor type 2 (NTS2) analgesic macrocyclic analog"],"prefix":"10.1016","volume":"141","author":[{"given":"Magali","family":"Chartier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Desgagn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Sousbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Rumsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Chevillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Th\u00e9roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loun\u00e8s","family":"Haroune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"C\u00f4t\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Longpr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Luc","family":"Boudreault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric","family":"Marsault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Sarret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2021.111861_bib1","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1186\/1471-2458-11-770","article-title":"Pain as a global public health priority","volume":"11","author":"Goldberg","year":"2011","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.biopha.2021.111861_bib2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.biopsych.2019.06.017","article-title":"Capturing novel non-opioid pain targets","volume":"87","author":"Woolf","year":"2020","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.biopha.2021.111861_bib3","first-page":"179","article-title":"Chronic pain in Canada\u2014prevalence, treatment, impact and the role of opioid analgesia","volume":"7","author":"Moulin","year":"2002","journal-title":"Pain\u00a0Res. Manag."},{"key":"10.1016\/j.biopha.2021.111861_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.abb.2018.10.011","article-title":"Recent progress in non-opioid analgesic peptides","volume":"660","author":"Perez de Vega","year":"2018","journal-title":"Arch. Biochem. Biophys."},{"issue":"4","key":"10.1016\/j.biopha.2021.111861_bib5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1139\/jpn.0627","article-title":"The role of neurotensin in central nervous system pathophysiology: what is the evidence?","volume":"31","author":"St-Gelais","year":"2006","journal-title":"J. Psychiatry Neurosci."},{"issue":"6","key":"10.1016\/j.biopha.2021.111861_bib6","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1080\/01616412.2016.1187826","article-title":"Pharmacological hypothermia: a potential for future stroke therapy?","volume":"38","author":"Liu","year":"2016","journal-title":"Neurol. Res."},{"issue":"3","key":"10.1016\/j.biopha.2021.111861_bib7","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.bbadis.2017.12.036","article-title":"Role of central neurotensin in regulating feeding: implications for the development and treatment of body weight disorders","volume":"1864","author":"Schroeder","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"10","key":"10.1016\/j.biopha.2021.111861_bib8","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/j.peptides.2006.04.025","article-title":"Neurotensin and pain modulation","volume":"27","author":"Dobner","year":"2006","journal-title":"Peptides"},{"issue":"7","key":"10.1016\/j.biopha.2021.111861_bib9","doi-asserted-by":"crossref","first-page":"840","DOI":"10.2174\/1381612820666141027124915","article-title":"The roles of neurotensin and its analogues in pain","volume":"21","author":"Feng","year":"2015","journal-title":"Curr. Pharm. Des."},{"issue":"10","key":"10.1016\/j.biopha.2021.111861_bib10","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.peptides.2006.03.037","article-title":"Brain neurotensin, psychostimulants, and stress--emphasis on neuroanatomical substrates","volume":"27","author":"Geisler","year":"2006","journal-title":"Peptides"},{"key":"10.1016\/j.biopha.2021.111861_bib11","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3389\/fendo.2013.00036","article-title":"Diverse roles of neurotensin agonists in the central nervous system","volume":"4","author":"Boules","year":"2013","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2021.111861_bib12","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejphar.2015.05.025","article-title":"Emerging role of neurotensin in regulation of the cardiovascular system","volume":"762","author":"Osadchii","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.biopha.2021.111861_bib13","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1016\/j.peptides.2005.12.016","article-title":"Effects of NT on gastrointestinal motility and secretion, and role in intestinal inflammation","volume":"27","author":"Zhao","year":"2006","journal-title":"Peptides"},{"key":"10.1016\/j.biopha.2021.111861_bib14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0014-2999(79)90415-1","article-title":"Neurotensin: antinocisponsive action in rodents","volume":"54","author":"Clineschmidt","year":"1979","journal-title":"Eur. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.biopha.2021.111861_bib15","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0196-9781(97)00145-9","article-title":"Comparative antipsychotic profiles of neurotensin and a related systemically active peptide agonist","volume":"18","author":"Sarhan","year":"1997","journal-title":"Peptides"},{"key":"10.1016\/j.biopha.2021.111861_bib16","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1749-6632.1982.tb31576.x","article-title":"Antinocisponsive effects of neurotensin and neurotensin-related peptides","volume":"400","author":"Clineschmidt","year":"1982","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2021.111861_bib17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.bbr.2006.09.016","article-title":"Interactions between NTS2 neurotensin and opioid receptors on two nociceptive responses assessed on the hot plate test in mice","volume":"175","author":"Bredeloux","year":"2006","journal-title":"Behav. Brain Res."},{"issue":"1","key":"10.1016\/j.biopha.2021.111861_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0006-8993(84)90619-X","article-title":"A mechanism for the analgesic effect of neurotensin as revealed by behavioral and electrophysiological techniques","volume":"324","author":"Behbehani","year":"1984","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/j.biopha.2021.111861_bib19","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/0014-2999(77)90236-9","article-title":"Neurotensin administered intracisternally inhibits responsiveness of mice to noxious stimuli","volume":"46","author":"Clineschmidt","year":"1977","journal-title":"Eur. J. Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2021.111861_bib20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0197-0186(88)90175-1","article-title":"Potentiation by thiorphan and bestatin of the naloxone-insensitive analgesic effects of neurotensin and neuromedin n","volume":"12","author":"Coquerel","year":"1988","journal-title":"Neurochem. Int."},{"issue":"3","key":"10.1016\/j.biopha.2021.111861_bib21","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0022-3565(25)32585-1","article-title":"Neurotensin-induced antinociception in mice: antagonism by thyrotropin-releasing hormone","volume":"217","author":"Osbahr","year":"1981","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.biopha.2021.111861_bib22","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/0960-894X(95)00155-M","article-title":"Reduced amide bond neurotensin 8-13 mimetics with potent in vivo activity","volume":"5","author":"Wustrow","year":"1995","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"11","key":"10.1016\/j.biopha.2021.111861_bib23","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.1021\/acschemneuro.9b00390","article-title":"Neurotensin analogues containing cyclic surrogates of tyrosine at position 11 improve NTS2 selectivity leading to analgesia without hypotension and hypothermia","volume":"10","author":"Eiselt","year":"2019","journal-title":"ACS Chem. Neurosci."},{"issue":"10","key":"10.1016\/j.biopha.2021.111861_bib24","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1073\/pnas.76.10.5368","article-title":"Alterations in nociception and body temperature after intracisternal administration of neurotensin, beta-endorphin, other endogenous peptides, and morphine","volume":"76","author":"Nemeroff","year":"1979","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1\u20132","key":"10.1016\/j.biopha.2021.111861_bib25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0006-8993(91)90139-M","article-title":"Structure-antinociceptive activity of neurotensin and some novel analogues in the periaqueductal gray region of the brainstem","volume":"557","author":"al-Rodhan","year":"1991","journal-title":"Brain Res"},{"issue":"9","key":"10.1016\/j.biopha.2021.111861_bib26","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1096\/fj.12-225540","article-title":"Spinal NTS2 receptor activation reverses signs of neuropathic pain","volume":"27","author":"T\u00e9treault","year":"2013","journal-title":"FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol."},{"issue":"1\u20133","key":"10.1016\/j.biopha.2021.111861_bib27","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejphar.2013.03.004","article-title":"Neurotensin and neurotensin receptors: characteristic, structure-activity relationship and pain modulation\u2014a review","volume":"716","author":"Kleczkowska","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2021.111861_bib28","series-title":"Neurotensin and Its Receptors, Reference Module in Neuroscience and Biobehavioral\u00a0Psychology","first-page":"1","author":"Sarret","year":"2018"},{"issue":"5","key":"10.1016\/j.biopha.2021.111861_bib29","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1097\/00001756-200104170-00044","article-title":"Localization of neurotensin NTS2 receptors in rat brain, using [3H]Levocabastine","volume":"12","author":"Asselin","year":"2001","journal-title":"Neuroreport"},{"issue":"1","key":"10.1016\/j.biopha.2021.111861_bib30","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/(SICI)1096-9861(19960909)373:1<76::AID-CNE7>3.0.CO;2-A","article-title":"Cellular distribution of neurotensin receptors in rat brain: immunohistochemical study using an antipeptide antibody against the cloned high affinity receptor","volume":"373","author":"Boudin","year":"1996","journal-title":"J. Comp. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2021.111861_bib31","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.pain.2004.12.031","article-title":"Neurotensin activation of the NTR1 on spinally-projecting serotonergic neurons in the rostral ventromedial medulla is antinociceptive","volume":"114","author":"Buhler","year":"2005","journal-title":"Pain"},{"issue":"4","key":"10.1016\/j.biopha.2021.111861_bib32","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/j.1471-4159.2007.05205.x","article-title":"Spinal NTS1 receptors regulate nociceptive signaling in a rat formalin tonic pain model","volume":"105","author":"Roussy","year":"2008","journal-title":"J. Neurochem."},{"issue":"36","key":"10.1016\/j.biopha.2021.111861_bib33","doi-asserted-by":"crossref","first-page":"8188","DOI":"10.1523\/JNEUROSCI.0810-05.2005","article-title":"Potent spinal analgesia elicited through stimulation of NTS2 neurotensin receptors","volume":"25","author":"Sarret","year":"2005","journal-title":"J. Neurosci.: Off. J. Soc. Neurosci."},{"issue":"4","key":"10.1016\/j.biopha.2021.111861_bib34","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/cne.10718","article-title":"Immunohistochemical distribution of NTS2 neurotensin receptors in the rat central nervous system","volume":"461","author":"Sarret","year":"2003","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.biopha.2021.111861_bib35","series-title":"Handbook of Chemical Neuroanatomy, Peptide Receptors, Pt II","first-page":"323","article-title":"Neurotensin receptors in the central nervous system","author":"Sarret","year":"2002"},{"issue":"3","key":"10.1016\/j.biopha.2021.111861_bib36","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/(SICI)1096-9861(19980511)394:3<344::AID-CNE6>3.0.CO;2-1","article-title":"Regional and cellular distribution of low affinity neurotensin receptor mRNA in adult and developing mouse brain","volume":"394","author":"Sarret","year":"1998","journal-title":"J. Comp. Neurol."},{"issue":"8","key":"10.1016\/j.biopha.2021.111861_bib37","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S0028-3908(00)00060-5","article-title":"Distribution of the neurotensin receptor NTS1 in the rat CNS studied using an amino-terminal directed antibody","volume":"39","author":"Fassio","year":"2000","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.biopha.2021.111861_bib38","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.pbb.2004.12.005","article-title":"Antinociceptive, hypothermic, hypotensive, and reinforcing effects of a novel neurotensin receptor agonist, NT69L, in rhesus monkeys","volume":"80","author":"Fantegrossi","year":"2005","journal-title":"Pharmacol.\u00a0Biochem.\u00a0Behav."},{"issue":"5","key":"10.1016\/j.biopha.2021.111861_bib39","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0143-4179(96)90002-5","article-title":"Peripheral neurotensin participates in the modulation of pre- and postprandial intestinal motility in rats","volume":"30","author":"Pellissier","year":"1996","journal-title":"Neuropeptides"},{"key":"10.1016\/j.biopha.2021.111861_bib40","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3389\/fchem.2020.00406","article-title":"Insightful backbone modifications preventing proteolytic degradation of neurotensin analogs improve NTS1-induced protective hypothermia","volume":"8","author":"Previti","year":"2020","journal-title":"Front. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2021.111861_bib41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1432-1033.1982.tb05913.x","article-title":"Synthesis and characterization of neurotensin analogues for structure\/activity relationship studies. Acetyl-neurotensin-(8--13) is the shortest analogue with full binding and pharmacological activities","volume":"124","author":"Granier","year":"1982","journal-title":"Eur. J. Biochem."},{"issue":"3","key":"10.1016\/j.biopha.2021.111861_bib42","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.pain.2007.06.010","article-title":"Neurotensin-produced antinociception in the rostral ventromedial medulla is partially mediated by spinal cord norepinephrine","volume":"135","author":"Buhler","year":"2008","journal-title":"Pain"},{"issue":"4","key":"10.1016\/j.biopha.2021.111861_bib43","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ejpain.2011.07.008","article-title":"Intrathecal administration of NTS1 agonists reverses nociceptive behaviors in a rat model of neuropathic pain","volume":"16","author":"Guillemette","year":"2012","journal-title":"Eur. J. Pain"},{"issue":"1","key":"10.1016\/j.biopha.2021.111861_bib44","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bbr.2012.03.044","article-title":"NTS1 and NTS2 mediate analgesia following neurotensin analog treatment in a mouse model for visceral pain","volume":"232","author":"Smith","year":"2012","journal-title":"Behav. Brain Res."},{"issue":"1","key":"10.1016\/j.biopha.2021.111861_bib45","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1523\/JNEUROSCI.19-01-00503.1999","article-title":"Identification of the receptor subtype involved in the analgesic effect of neurotensin","volume":"19","author":"Dubuc","year":"1999","journal-title":"J. Neurosci.: Off. J. Soc. Neurosci."},{"key":"10.1016\/j.biopha.2021.111861_bib46","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.brainres.2009.10.050","article-title":"NT79: a novel neurotensin analog with selective behavioral effects","volume":"1308","author":"Boules","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.biopha.2021.111861_bib47","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1744-8069-5-38","article-title":"Evidence for a role of NTS2 receptors in the modulation of tonic pain sensitivity","volume":"5","author":"Roussy","year":"2009","journal-title":"Mol. Pain"},{"issue":"6","key":"10.1016\/j.biopha.2021.111861_bib48","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41573-020-0062-z","article-title":"Advances in therapeutic peptides targeting G protein-coupled receptors","volume":"19","author":"Davenport","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.biopha.2021.111861_bib49","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1021\/acsmedchemlett.7b00500","article-title":"In search of the optimal macrocyclization site for neurotensin","volume":"9","author":"Sousbie","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"issue":"16","key":"10.1016\/j.biopha.2021.111861_bib50","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.1021\/acs.jmedchem.8b00175","article-title":"Structural optimization and characterization of potent analgesic macrocyclic analogues of neurotensin (8-13)","volume":"61","author":"Sousbie","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2021.111861_bib51","series-title":"Practical Medicinal Chemistry with Macrocycles: Design, Synthesis, and Case Studies","author":"Marsault","year":"2017"},{"issue":"7","key":"10.1016\/j.biopha.2021.111861_bib52","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1021\/jm1012374","article-title":"Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery","volume":"54","author":"Marsault","year":"2011","journal-title":"J. Med Chem."},{"issue":"11","key":"10.1016\/j.biopha.2021.111861_bib53","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.4155\/fmc.12.93","article-title":"Macrocycles in new drug discovery","volume":"4","author":"Mallinson","year":"2012","journal-title":"Future Med. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2021.111861_bib54","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1021\/jm700925k","article-title":"Synthesis and biological effects of c(Lys-Lys-Pro-Tyr-Ile-Leu-Lys-Lys-Pro-Tyr-Ile-Leu) (JMV2012), a new analogue of neurotensin that crosses the blood-brain barrier","volume":"51","author":"Bredeloux","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2021.111861_bib55","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1021\/jm200006c","article-title":"Discovery of highly potent and neurotensin receptor 2 selective neurotensin mimetics","volume":"54","author":"Einsiedel","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2021.111861_bib56","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1021\/acs.jmedchem.6b01848","article-title":"Use of molecular modeling to design selective NTS2 neurotensin analogues","volume":"60","author":"Fanelli","year":"2017","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.biopha.2021.111861_bib57","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/open.201402031","article-title":"Structure-based evolution of subtype-selective neurotensin receptor ligands","volume":"3","author":"Schaab","year":"2014","journal-title":"ChemistryOpen"},{"issue":"1","key":"10.1016\/j.biopha.2021.111861_bib58","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/cmdc.201200376","article-title":"Development of a metabolically stable neurotensin receptor 2 (NTS2) ligand","volume":"8","author":"Held","year":"2013","journal-title":"ChemMedChem"},{"issue":"10","key":"10.1016\/j.biopha.2021.111861_bib59","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1039\/c1ob05292f","article-title":"Radical arylation of tyrosine and its application in the synthesis of a highly selective neurotensin receptor 2 ligand","volume":"9","author":"Pratsch","year":"2011","journal-title":"Org. Biomol. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2021.111861_bib60","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.bmc.2016.10.039","article-title":"NTS2-selective neurotensin mimetics with tetrahydrofuran amino acids","volume":"25","author":"Simeth","year":"2017","journal-title":"Bioorg. Med. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2021.111861_bib61","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1124\/mol.60.6.1392","article-title":"Agonism, inverse agonism, and neutral antagonism at the constitutively active human neurotensin receptor 2","volume":"60","author":"Richard","year":"2001","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2021.111861_bib62","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2021.111861_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"8","author":"Kilkenny","year":"2010","journal-title":"PLOS Biol."},{"issue":"1","key":"10.1016\/j.biopha.2021.111861_bib64","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0031-9384(95)00046-L","article-title":"Tail-flick test. I: impact of a suprathreshold exposure to radiant heat on pain reactivity in rats","volume":"58","author":"Kallina","year":"1995","journal-title":"Physiol. Behav."},{"issue":"1","key":"10.1016\/j.biopha.2021.111861_bib65","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0304-3959(92)90003-T","article-title":"The formalin test: an evaluation of the method","volume":"51","author":"Tj\u00f8lsen","year":"1992","journal-title":"Pain"},{"issue":"3\u20134","key":"10.1016\/j.biopha.2021.111861_bib66","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF02769177","article-title":"The role of excitatory amino acid receptors and intracellular messengers in persistent nociception after tissue injury in rats","volume":"7","author":"Coderre","year":"1993","journal-title":"Mol. Neurobiol."},{"issue":"2","key":"10.1016\/j.biopha.2021.111861_bib67","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0304-3959(77)90130-0","article-title":"The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats","volume":"4","author":"Dubuisson","year":"1977","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.biopha.2021.111861_bib68","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0165-0270(94)90144-9","article-title":"Quantitative assessment of tactile allodynia in the rat paw","volume":"53","author":"Chaplan","year":"1994","journal-title":"J. Neurosci. Methods"},{"issue":"1","key":"10.1016\/j.biopha.2021.111861_bib69","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jneumeth.2008.12.001","article-title":"A simple and rapid method to collect the cerebrospinal fluid of rats and its application for the assessment of drug penetration into the central nervous system","volume":"178","author":"Nirogi","year":"2009","journal-title":"J. Neurosci. Methods"},{"issue":"7","key":"10.1016\/j.biopha.2021.111861_bib70","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bph.14153","article-title":"Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers","volume":"175","author":"Curtis","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2021.111861_bib71","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1021\/jm400887j","article-title":"Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?","volume":"57","author":"Giordanetto","year":"2014","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2021.111861_bib72","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/med.21639","article-title":"A gold mine for drug discovery: strategies to develop cyclic peptides into therapies","volume":"40","author":"Jing","year":"2020","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.biopha.2021.111861_bib73","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cbpa.2017.02.006","article-title":"Cyclic peptide therapeutics: past, present and future","volume":"38","author":"Zorzi","year":"2017","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.biopha.2021.111861_bib74","series-title":"Practical Medicinal Chemistry with Macrocycles: Design, Synthesis, and Case Studies","first-page":"411","article-title":"Overview of macrocycles in clinical development and clinically used","author":"Stotani","year":"2017"},{"issue":"2","key":"10.1016\/j.biopha.2021.111861_bib75","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1021\/jm00002a006","article-title":"Design and structure-activity relationships of C-terminal cyclic neurotensin fragment analogues","volume":"38","author":"Sefler","year":"1995","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2021.111861_bib76","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0143-4179(96)90066-9","article-title":"Functional activity of new C-terminal cyclic-neurotensin fragment analogs","volume":"30","author":"Akunne","year":"1996","journal-title":"Neuropeptides"},{"issue":"1","key":"10.1016\/j.biopha.2021.111861_bib77","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/0304-3940(96)13074-3","article-title":"cyclic 8-13 neurotensin fragment analog appears less exposed to neprilysin when it crosses the blood-brain barrier than the cerebrospinal fluid-brain barrier in mice","volume":"217","author":"Van Kemmel","year":"1996","journal-title":"Neurosci. Lett."},{"issue":"17","key":"10.1016\/j.biopha.2021.111861_bib78","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1016\/S0960-894X(99)00420-5","article-title":"Preparation and receptor binding affinities of cyclic C-terminal neurotensin (8-13) and (9-13) analogues","volume":"9","author":"Lundquist","year":"1999","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.biopha.2021.111861_bib79","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1021\/acschemneuro.6b00097","article-title":"Identification of 2-({[1-(4-Fluorophenyl)-5-(2-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl}amino)tricyc lo[3.3.1.13,7]decane-2-carboxylic acid (NTRC-844) as a selective antagonist for the rat neurotensin receptor type 2","volume":"7","author":"Thomas","year":"2016","journal-title":"ACS Chem. Neurosci."},{"issue":"8","key":"10.1016\/j.biopha.2021.111861_bib80","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/bip.20983","article-title":"Conformational constraint in protein ligand design and the inconsistency of binding entropy","volume":"89","author":"Udugamasooriya","year":"2008","journal-title":"Biopolymers"},{"issue":"42","key":"10.1016\/j.biopha.2021.111861_bib81","doi-asserted-by":"crossref","first-page":"7435","DOI":"10.2174\/138161281942140105165646","article-title":"Hybrid opioid\/non-opioid ligands in pain research","volume":"19","author":"Kleczkowska","year":"2013","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"10.1016\/j.biopha.2021.111861_bib82","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0006-8993(01)02511-2","article-title":"Intraperitoneal injection of antisense peptide nucleic acids targeted to the mu receptor decreases response to morphine and receptor protein levels in rat brain","volume":"904","author":"McMahon","year":"2001","journal-title":"Brain Res"},{"issue":"4","key":"10.1016\/j.biopha.2021.111861_bib83","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.neuroscience.2010.08.016","article-title":"Altered morphine-induced analgesia in neurotensin type 1 receptor null mice","volume":"170","author":"Roussy","year":"2010","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.biopha.2021.111861_bib84","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0006-8993(00)02179-X","article-title":"Antinociception produced by mu opioid receptor activation in the amygdala is partly dependent on activation of mu opioid and neurotensin receptors in the ventral periaqueductal gray","volume":"865","author":"Tershner","year":"2000","journal-title":"Brain Res."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2021.111861_bib85","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0006-8993(97)81698-8","article-title":"Opioid-induced release of neurotensin in the periaqueductal gray matter of freely moving rats","volume":"774","author":"Stiller","year":"1997","journal-title":"Brain Res"},{"issue":"11","key":"10.1016\/j.biopha.2021.111861_bib86","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S1474-4422(13)70193-5","article-title":"Combination pharmacotherapy for management of chronic pain: from bench to bedside","volume":"12","author":"Gilron","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.biopha.2021.111861_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.04.025","article-title":"Combining opioids and non-opioids for pain management: current status","volume":"158","author":"Li","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2021.111861_bib88","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejphar.2019.01.048","article-title":"The combination of opioid and neurotensin receptor agonists improves their analgesic\/adverse effect ratio","volume":"848","author":"Eiselt","year":"2019","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2021.111861_bib89","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.brainres.2009.07.086","article-title":"NT69L, a novel analgesic, shows synergy with morphine","volume":"1294","author":"Boules","year":"2009","journal-title":"Brain Res."},{"issue":"5\u20136","key":"10.1016\/j.biopha.2021.111861_bib90","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/FBP.0b013e3283474a3a","article-title":"Analgesic synergy of neurotensin receptor subtype 2 agonist NT79 and morphine","volume":"22","author":"Boules","year":"2011","journal-title":"Behav. Pharm."},{"key":"10.1016\/j.biopha.2021.111861_bib91","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1749-6632.1982.tb31575.x","article-title":"Neurotensin and thermoregulation","volume":"400","author":"Bissette","year":"1982","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.biopha.2021.111861_bib92","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.expneurol.2015.02.029","article-title":"Pharmacologically induced hypothermia attenuates traumatic brain injury in neonatal rats","volume":"267","author":"Gu","year":"2015","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.biopha.2021.111861_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2019.113133","article-title":"Pharmacological hypothermia induced neurovascular protection after severe stroke of transient middle cerebral artery occlusion in mice","volume":"325","author":"Zhao","year":"2020","journal-title":"Exp. Neurol."},{"issue":"7","key":"10.1016\/j.biopha.2021.111861_bib94","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1096\/fj.11-201822","article-title":"A novel stroke therapy of pharmacologically induced hypothermia after focal cerebral ischemia in mice","volume":"26","author":"Choi","year":"2012","journal-title":"FASEB J."},{"issue":"2\u20133","key":"10.1016\/j.biopha.2021.111861_bib95","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0014-2999(96)00943-0","article-title":"Mode and mechanism of neurotensin action in rat proximal colon","volume":"319","author":"Mul\u00e8","year":"1997","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2021.111861_bib96","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1124\/jpet.300.1.305","article-title":"The effects of deleting the mouse neurotensin receptor NTR1 on central and peripheral responses to neurotensin","volume":"300","author":"Pettibone","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"12","key":"10.1016\/j.biopha.2021.111861_bib97","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.1073\/pnas.96.12.7053","article-title":"Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression","volume":"96","author":"Tyler","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"10.1016\/j.biopha.2021.111861_bib98","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.euroneuro.2009.01.004","article-title":"Involvement of the neurotensin receptor 1 in the behavioral effects of two neurotensin agonists, NT-2 and NT69L: lack of hypothermic, antinociceptive and antipsychotic actions in receptor knockout mice","volume":"19","author":"Mechanic","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2021.111861_bib99","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1476-5381.1996.tb15216.x","article-title":"Antagonism by SR 48692 of mechanical responses to neurotensin in rat intestine","volume":"117","author":"Mule","year":"1996","journal-title":"Br. J. Pharm."},{"issue":"19","key":"10.1016\/j.biopha.2021.111861_bib100","doi-asserted-by":"crossref","first-page":"6854","DOI":"10.1016\/S0021-9258(19)43429-7","article-title":"The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami","volume":"248","author":"Carraway","year":"1973","journal-title":"J. Biol. Chem."},{"issue":"22","key":"10.1016\/j.biopha.2021.111861_bib101","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/0024-3205(81)90589-0","article-title":"Mechanism of neurotensin-induced pressor effect and tachycardia in guinea pigs","volume":"28","author":"K\u00e9rouac","year":"1981","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.biopha.2021.111861_bib102","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0014-2999(81)90469-6","article-title":"The hypotensive effect of centrally administered neurotensin in rats","volume":"69","author":"Rioux","year":"1981","journal-title":"Eur. J. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2021.111861_bib103","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0021-5198(19)52782-2","article-title":"Possible mechanisms of the triphasic effects of neurotensin on the rat blood pressure","volume":"31","author":"Oishi","year":"1981","journal-title":"Jpn J. Pharm."},{"issue":"4","key":"10.1016\/j.biopha.2021.111861_bib104","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0014-2999(78)90140-1","article-title":"Effects of neurotensin on isolated intestinal smooth muscles","volume":"50","author":"Kitabgi","year":"1978","journal-title":"Eur. J. Pharm."},{"issue":"5 Pt 1","key":"10.1016\/j.biopha.2021.111861_bib105","first-page":"G767","article-title":"Mechanisms of neurotensin-induced inhibition in rat ileal smooth muscle","volume":"263","author":"Allescher","year":"1992","journal-title":"Am. J. Physiol."},{"issue":"4","key":"10.1016\/j.biopha.2021.111861_bib106","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0196-9781(82)90164-4","article-title":"The stability and metabolism of intravenously administered neurotensin in the rat","volume":"3","author":"Aronin","year":"1982","journal-title":"Peptides"},{"issue":"2","key":"10.1016\/j.biopha.2021.111861_bib107","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1471-4159.1983.tb04753.x","article-title":"Degradation of neurotensin by rat brain synaptic membranes: involvement of a thermolysin-like metalloendopeptidase (enkephalinase), angiotensin-converting enzyme, and other unidentified peptidases","volume":"41","author":"Checler","year":"1983","journal-title":"J. Neurochem."},{"issue":"5","key":"10.1016\/j.biopha.2021.111861_bib108","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/j.1471-4159.1984.tb05386.x","article-title":"Inactivation of neurotensin by rat brain synaptic membranes. Cleavage at the Pro10-Tyr11 bond by endopeptidase 24.11 (enkephalinase) and a peptidase different from proline-endopeptidase","volume":"43","author":"Checler","year":"1984","journal-title":"J. Neurochem."},{"issue":"5","key":"10.1016\/j.biopha.2021.111861_bib109","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/j.1471-4159.1985.tb07220.x","article-title":"Inactivation of neurotensin by rat brain synaptic membranes partly occurs through cleavage at the Arg8-Arg9 peptide bond by a metalloendopeptidase","volume":"45","author":"Checler","year":"1985","journal-title":"J. Neurochem."},{"issue":"24","key":"10.1016\/j.biopha.2021.111861_bib110","doi-asserted-by":"crossref","first-page":"11274","DOI":"10.1016\/S0021-9258(18)67379-X","article-title":"Purification and characterization of a novel neurotensin-degrading peptidase from rat brain synaptic membranes","volume":"261","author":"Checler","year":"1986","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2021.111861_bib111","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1021\/cr040669e","article-title":"Proteases universally recognize beta strands in their active sites","volume":"105","author":"Tyndall","year":"2005","journal-title":"Chem. Rev."},{"issue":"10","key":"10.1016\/j.biopha.2021.111861_bib112","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00228-017-2301-8","article-title":"Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm","volume":"73","author":"Taneja","year":"2017","journal-title":"Eur. J. Clin. Pharm."},{"issue":"5","key":"10.1016\/j.biopha.2021.111861_bib113","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.neuron.2019.02.019","article-title":"Composite pain biomarker signatures for objective assessment and effective treatment","volume":"101","author":"Tracey","year":"2019","journal-title":"Neuron"},{"issue":"10","key":"10.1016\/j.biopha.2021.111861_bib114","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1158\/1078-0432.CCR-13-3132","article-title":"Pharmacodynamic biomarkers: falling short of the mark?","volume":"20","author":"Gainor","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.biopha.2021.111861_bib115","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41582-020-0362-2","article-title":"Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities","volume":"16","author":"Davis","year":"2020","journal-title":"Nat. Rev. Neurol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221006430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221006430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T21:32:17Z","timestamp":1776461537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221006430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":115,"alternative-id":["S0753332221006430"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111861","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacodynamic and pharmacokinetic profiles of a neurotensin receptor type 2 (NTS2) analgesic macrocyclic analog","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111861","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"111861"}}